NEW YORK (GenomeWeb) – Ag-bio firm Arcadia Biosciences announced today that has it acquired a worldwide, nonexclusive license to the Broad Institute's intellectual property on CRISPR-Cas9 genome-editing technology.
According to Arcadia, the research-use license allows it to use the patented technology to develop nutritional and agricultural productivity traits in its core crops. Additional terms of the deal were not disclosed.
"CRISPR-Cas9 is a high-throughput, cost-effective development tool that is complementary to our ongoing Tilling [advanced breeding technology] and transgenic development platforms," Arcadia President and CEO Raj Ketkar said in a statement. "We expect this technology will significantly improve the time to market for a number of our innovative traits addressing large-acre, high-value crops."